These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 26116314)

  • 1. Neuroprotection in Parkinson's disease: a difficult challenge.
    Stocchi F
    Lancet Neurol; 2015 Aug; 14(8):780-781. PubMed ID: 26116314
    [No Abstract]   [Full Text] [Related]  

  • 2. Parkinson disease: Laying the foundations for disease-modifying therapies in PD.
    Brundin P; Wyse R
    Nat Rev Neurol; 2015 Oct; 11(10):553-5. PubMed ID: 26303855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New preclinical model are required to discover neuroprotective compound in Parkinson's disease.
    Segura-Aguilar J
    Pharmacol Res; 2017 May; 119():490. PubMed ID: 27894922
    [No Abstract]   [Full Text] [Related]  

  • 4. Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial.
    NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators
    Lancet Neurol; 2015 Aug; 14(8):795-803. PubMed ID: 26116315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to comment by Juan Segura-Aguilar: New preclinical model are required to discover neuroprotective compound in Parkinson's disease.
    Mattace Raso G; Avagliano C; Calignano A
    Pharmacol Res; 2017 May; 119():491-492. PubMed ID: 27890814
    [No Abstract]   [Full Text] [Related]  

  • 6. Why hasn't neuroprotection worked in Parkinson's disease?
    Kieburtz K; Ravina B
    Nat Clin Pract Neurol; 2007 May; 3(5):240-1. PubMed ID: 17479072
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical aspects of neuroprotection in Parkinson's disease.
    Przuntek H
    J Neural Transm Suppl; 1994; 43():163-9. PubMed ID: 7884398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neuroprotective effect of baicalein in patients with Parkinson's disease].
    Yu X; He G; Du G
    Zhongguo Zhong Yao Za Zhi; 2012 Feb; 37(4):421-5. PubMed ID: 22667137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson's disease.
    Carta AR; Simuni T
    Expert Opin Investig Drugs; 2015 Feb; 24(2):219-27. PubMed ID: 25227476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroprotective strategies in Parkinson's disease : an update on progress.
    Mandel S; Grünblatt E; Riederer P; Gerlach M; Levites Y; Youdim MB
    CNS Drugs; 2003; 17(10):729-62. PubMed ID: 12873156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroprotection and neurorestoration as experimental therapeutics for Parkinson's disease.
    Francardo V; Schmitz Y; Sulzer D; Cenci MA
    Exp Neurol; 2017 Dec; 298(Pt B):137-147. PubMed ID: 28988910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotection in Parkinson's disease: an elusive goal.
    Biglan KM; Ravina B
    Semin Neurol; 2007 Apr; 27(2):106-12. PubMed ID: 17390255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroprotection in Parkinson's disease: and now for something completely different?
    Lang AE
    Lancet Neurol; 2006 Dec; 5(12):990-1. PubMed ID: 17110271
    [No Abstract]   [Full Text] [Related]  

  • 14. Parkinson's and Alzheimer's diseases: protein aggregations and neuroprotection.
    Gozes I
    J Mol Neurosci; 2004; 24(3):333-6. PubMed ID: 15655257
    [No Abstract]   [Full Text] [Related]  

  • 15. Statins and Parkinson's: A complex interaction.
    Carroll CB; Wyse RKH; Grosset DG
    Mov Disord; 2019 Jul; 34(7):934-935. PubMed ID: 31322771
    [No Abstract]   [Full Text] [Related]  

  • 16. Designing neuroprotection trials in Parkinson's disease.
    Kieburtz K
    Ann Neurol; 2003; 53 Suppl 3():S100-7; discussion S107-9. PubMed ID: 12666102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parkinson's disease, insulin resistance and novel agents of neuroprotection.
    Aviles-Olmos I; Limousin P; Lees A; Foltynie T
    Brain; 2013 Feb; 136(Pt 2):374-84. PubMed ID: 22344583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroprotective actions of coenzyme Q10 in Parkinson's disease.
    Sharma S; Kheradpezhou M; Shavali S; El Refaey H; Eken J; Hagen C; Ebadi M
    Methods Enzymol; 2004; 382():488-509. PubMed ID: 15047119
    [No Abstract]   [Full Text] [Related]  

  • 19. Neuroprotective therapy for Parkinson's disease.
    Koller WC
    Exp Neurol; 1997 Mar; 144(1):24-8. PubMed ID: 9126147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New hope for mechanism-based treatment of Parkinson's disease.
    Bradbury J
    Drug Discov Today; 2005 Jan; 10(2):80-1. PubMed ID: 15718152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.